The Most Popular Coronavirus Stock May Lose Half Its Value by 2023

This has been a trying year for America and the world. The coronavirus disease 2019 (COVID-19) pandemic has infected more than 69 million people worldwide (almost 16 million in the U.S.) and has led to the deaths of nearly 1.6 million people, per Johns Hopkins University of Medicine. The U.S. is closing in on 300,000 deaths from COVID-19 since the outbreak began.

But there also appears to be light at the end of the tunnel. In November, a handful of drug developers released positive late-stage interim and final analysis data from their ongoing COVID-19 vaccine trials. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced 95% vaccine effectiveness (VE) for BNT162b2 in a final analysis of its phase 3 study.

Meanwhile, Moderna (NASDAQ: MRNA) announced that its vaccine candidate (mRNA-1273) produced a VE of 94.1% in a late-stage primary efficacy analysis in its COVE study. With researchers expecting a VE more in line with influenza (50% to 60%), a 90%+ VE gives the U.S. and world a real chance to halt the pandemic in its tracks within the next year. 

Continue reading

Source Fool.com